Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Sarcoma 1Papillary Thyroid Microcarcinoma 1Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Carcinoma 1

Interventions

Doxorubicin 80Ifosfamide 54Radiotherapy 43Filgrastim 41Gemcitabine 38Cyclophosphamide 34Etoposide 26Vincristine 24Cisplatin 24Docetaxel 23pazopanib 21Trabectedin 19Carboplatin 17pembrolizumab 15Peripheral Blood Stem Cell Transplantation 14eribulin 12Mesna 12Melphalan 12Sorafenib 11Sirolimus 11Irinotecan 11Granulocyte Colony-Stimulating Factor 11Bevacizumab 11Topotecan 10Paclitaxel 10Imatinib Mesylate 10Chemotherapy, Adjuvant 10pegfilgrastim 9Temozolomide 9Surgical Procedures, Operative 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sarcoma × Transurethral Resection of Prostate × Clear all
NCT03993678 2025-12-30

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

Swiss Cancer Institute

Phase 1/2 Completed
28 enrolled
DermatologicSarcoma

Melanoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡